Description
Buy ADB-BUTINACA Online | Secured Tracked Logistics EU
Order High-Purity ADB-BUTINACA for Laboratory Research
Looking to secure a reliable supply of ADB-BUTINACA to buy ADB-BUTINACA online for forensic profiling, mass spectrometry calibration, or neuroreceptor transport assays? As a leading European chemical distributor, we deliver certified, premium-grade ADB-BUTINACA Crystal synthesized under strict laboratory quality control parameters. When you buy ADB-BUTINACA online through our encrypted portal, you receive a highly stable analytical reference standard optimized for in vitro testing.
We cater exclusively to corporate entities, academic institutions, and contract research organizations (CROs). Whether your project requires you to buy ADB-BUTINACA online for retail gram quantities or a long-term bulk ADB-BUTINACA supplier contract, our logistics network ensures consistent purity across every batch.
Technical Specifications & Product Identification Data
- Systematic IUPAC Nomenclature: N-(1-amino-3,3-dimethyl-1-oxobutand-2-yl)-1-butyl-1H-indazole-3-carboxamide
- Standard CAS Registry Number: 2398509-08-1 (Free Base Form)
- Molecular Formula: C₁₈H₂₆N₄O₂ (Refined Crystalline Form)
- Exact Molar Mass: 330.43 g/mol
- Physical Presentation: Highly stable, fine white to off-white translucent large crystal structures or dense powder mass
- Structural Classification: Indazole-3-carboxamide synthetic cannabinoid derivative and non-classical synthetic agonist featuring a tert-butyl side group.
Theoretical Pharmacology & Documented Adverse Effects
Before you buy ADB-BUTINACA online, note that in vitro transport assays classify it as an ultra-potent non-classical synthetic agonist. Mechanistically, it functions as a highly selective CB₁ receptor full agonist, displaying binding affinities exponentially more potent than phytocannabinoids. It can completely activate active pathways at minute milligram thresholds.
Exposure triggers extreme, life-threatening physiological and neurological overstimulation. Documented systemic effects include acute severe tachycardia, extreme hypertensive strain, acute kidney injury, induced hypokalemia, and localized convulsions. Clinical warning frameworks state that ADB-BUTINACA exposure carries profound risk of drug-induced catatonia, respiratory arrest, and permanent neurological deficits if handling protocols crash.
Legal Status & European Regulations
The international legal framework surrounding indazole-based synthetic cannabinoids is zero-tolerance and heavily monitored:
-
- European Union (EU-Wide Prohibition): Following rapid risk assessments by the European Union Drugs Agency (EUDA), ADB-BUTINACA is classified as an illicit drug and banned uniformly across all EU Member States. National drug schedules—including Germany’s BtMG (Anlage I) and equivalent strict generic groupings in France and Poland—prohibit distribution outside specialized state-licensed scientific laboratories.
- United Kingdom: Strictly criminalized as a Class B controlled substance under the Misuse of Drugs Act 1971 due to sweeping synthetic cannabinoid core framework legislation.
- Shipping Policy: Orders addressed to private residential zip codes or unauthorized territories will be delivered securely and discretely at you risk and responsibility
Authorized Research Use & Safety Warning
The compound ADB-BUTINACA is a synthetic substance classified strictly as an analytical reagent or laboratory reference standard. It is not intended for human or veterinary consumption. Ingestion or accidental exposure poses severe, life-threatening health risks and is illegal under various international and national drug control frameworks. By placing this item into your cart, please ensure that you check the legality status of any product you purchase on our website as we cannot be held responsible for it.
Frequently Asked Questions (FAQ)
What are the primary health risks associated with ADB-BUTINACA?
As a non-classical synthetic agonist, accidental exposure to ADB-BUTINACA poses critical medical dangers, including myocardial infarction (heart attack), severe generalized seizures, sudden catatonia, and respiratory depression.
How does ADB-BUTINACA differ from classical cannabinoids like THC?
ADB-BUTINACA does not share the classic dibenzopyran ring structure of THC. Instead, it features a totally synthetic indazole-3-carboxamide core coupled with a distinct amino-oxobutane tail. This creates an extremely rigid spatial structure that fully activates CB₁ receptor targets at a fraction of the weight required for classic phytocannabinoids.
Can this material be used for consumer testing?
No. This compound is synthesized and handled strictly as an analytical reference standard. It is not approved for human or veterinary consumption, and any such application is completely illegal and carries life-threatening health and legal consequences.
